Latest Hemp Foods News

Elixinol Wellness has lifted combined hemp sales 12% to $6.41 million in the first nine months of 2026, while unaudited gross profit rose 41%. Two major grocery programs are now fully supplied through 2027, with Hemp Gold Protein due back at Costco in Australia and New Zealand.

Elixinol Wellness has finalized the divestment of its US operations to Ananda Health, securing upfront and deferred payments totaling approximately A$465,000. This move refocuses the company on its Australian health and wellness portfolio while reducing exposure to US regulatory risks.

Elixinol Wellness (ASX: EXL) has posted a record quarterly revenue of A$4.3 million alongside a 45% gross margin, marking a clear shift from its US CBD origins to a diversified Australian wellness platform. Cost reductions and disciplined cash flow management underpin the company’s readiness to scale.

Elixinol Wellness Ltd reported a 9.5% revenue increase in Q4 FY25 alongside a 30% cut in operating costs, achieving its first underlying operating cash flow positive quarter. The company’s strategic acquisitions and e-commerce growth underpin a clear path to profitability.

Elixinol Wellness has amended acquisition terms for The Healthy Chef after its US distributor exited, reducing earnout payments and refocusing growth efforts on Australia.

Elixinol Wellness reported steady Q3 revenue with a notable 300bps gross margin improvement, driven by e-commerce and core brands, while executing cost reduction initiatives supported by a $2.5 million capital raise.

Elixinol Wellness has raised $2.5 million through a well-supported placement and appointed industry veteran Gavin Evans as strategic advisor to drive its next phase of growth and operational reset.

Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.6 million for the first half of 2025, driven by Healthy Chef and Hemp Foods Australia, alongside improved gross margins. However, integration expenses weighed on profitability, resulting in an adjusted EBITDA loss of $2.2 million.

Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.64 million for the half-year ended June 2025, yet its net loss widened by 12.2% to $3.09 million, reflecting higher marketing and restructuring expenses following recent acquisitions.

Elixinol Wellness reported a 10.8% revenue increase in Q2 2025, supported by improved cash receipts and a focused cost containment program. The company secured new funding and launched a menopause-targeted product, positioning itself for margin growth and profitability in H2.

Elixinol Wellness reported a 13.7% year-on-year revenue increase in Q1 FY25, despite a softer quarter compared to record Q4, with ecommerce momentum and strategic initiatives setting the stage for margin recovery and growth in H2.

Elixinol Wellness delivered a standout Q4 FY24 performance with a 71% jump in cash receipts and a 64% rise in revenue, driven by key acquisitions and operational efficiencies. The company edges closer to EBITDA break-even, setting the stage for growth in 2025.